Table 2:

Preventive and therapeutic vaccines

	Agent	Targeted health problem	Result	Clinical/non clinical stage	References
1	Vaccinia construct-GP350	NPC	Vaccine was immunogenic	Phase I (May be discontinued)	[148]
2	gp350/AS04 vaccine	Infectious mononucleosis	Safety and immunogenicity assessed. Infectious mononucleosis prevented	Phase II	[148]
3	pcDNA3.1-LMP1	NPC	Tumor free when vaccinated before tumor induction in xenograft model	Pre-clinical	[150]
4	Mytomycin C-Fab fragments	NPC cell line HNE2-LMP1	Increased apoptosis in-vitro Increased tumor suppression in-vivo xenograft model	Pre-clinical	[151]
5	LMP1-TES1/CTAR1 specific antibody	NPC cell line HNE2-LMP1	Inhibited cell growth in-vitro	Pre-clinical	[153]
6	LMP1-specific IgG antibody	ENKTL**	Induced apoptosis	Pre-clinical	[155]

^**extranodal nasal-type natural killer (NK)/T-cell lymphoma (ENKTL)